Harvard Bioscience Statistics
Total Valuation
HBIO has a market cap or net worth of $172.30 million. The enterprise value is $210.79 million.
| Market Cap | 172.30M |
| Enterprise Value | 210.79M |
Important Dates
The next estimated earnings date is Tuesday, April 30, 2024, before market open.
| Earnings Date | Apr 30, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
HBIO has 43.40 million shares outstanding. The number of shares has increased by 2.43% in one year.
| Shares Outstanding | 43.40M |
| Shares Change (YoY) | +2.43% |
| Shares Change (QoQ) | -0.10% |
| Owned by Insiders (%) | 7.29% |
| Owned by Institutions (%) | 78.38% |
| Float | 35.10M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 18.83 |
| PS Ratio | 1.53 |
| Forward PS | 1.47 |
| PB Ratio | 2.36 |
| P/FCF Ratio | 14.70 |
| PEG Ratio | 2.89 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 26.24, with an EV/FCF ratio of 17.99.
| EV / Earnings | n/a |
| EV / Sales | 1.88 |
| EV / EBITDA | 26.24 |
| EV / EBIT | 203.66 |
| EV / FCF | 17.99 |
Financial Position
The company has a current ratio of 1.85, with a Debt / Equity ratio of 0.59.
| Current Ratio | 1.85 |
| Quick Ratio | 0.77 |
| Debt / Equity | 0.59 |
| Debt / EBITDA | 5.32 |
| Debt / FCF | 3.65 |
| Interest Coverage | 0.29 |
Financial Efficiency
Return on equity (ROE) is -4.60%.
| Return on Equity (ROE) | -4.60% |
| Return on Assets (ROA) | -2.40% |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | $287,084 |
| Profits Per Employee | -$8,734 |
| Employee Count | 391 |
| Asset Turnover | 0.79 |
| Inventory Turnover | 1.81 |
Taxes
In the past 12 months, HBIO has paid $859,000 in taxes.
| Income Tax | 859,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -16.24% in the last 52 weeks. The beta is 1.45, so HBIO's price volatility has been higher than the market average.
| Beta (1Y) | 1.45 |
| 52-Week Price Change | -16.24% |
| 50-Day Moving Average | 4.36 |
| 200-Day Moving Average | 4.52 |
| Relative Strength Index (RSI) | 41.72 |
| Average Volume (30 Days) | 86,558 |
Short Selling Information
The latest short interest is 636,652, so 1.47% of the outstanding shares have been sold short.
| Short Interest | 636,652 |
| Short Previous Month | 716,573 |
| Short % of Shares Out | 1.47% |
| Short % of Float | 1.81% |
| Short Ratio (days to cover) | 7.02 |
Income Statement
In the last 12 months, HBIO had revenue of $112.25 million and -$3.42 million in losses. Loss per share was -$0.08.
| Revenue | 112.25M |
| Gross Profit | 66.07M |
| Operating Income | 1.89M |
| Pretax Income | -2.56M |
| Net Income | -3.42M |
| EBITDA | 8.03M |
| EBIT | 1.04M |
| Loss Per Share | -$0.08 |
Balance Sheet
The company has $4.28 million in cash and $42.77 million in debt, giving a net cash position of -$38.49 million or -$0.89 per share.
| Cash & Cash Equivalents | 4.28M |
| Total Debt | 42.77M |
| Net Cash | -38.49M |
| Net Cash Per Share | -$0.89 |
| Equity / Book Value | 73.07M |
| Book Value Per Share | 1.68 |
| Working Capital | 22.50M |
Cash Flow
In the last 12 months, operating cash flow was $14.03 million and capital expenditures -$2.31 million, giving a free cash flow of $11.72 million.
| Operating Cash Flow | 14.03M |
| Capital Expenditures | -2.31M |
| Free Cash Flow | 11.72M |
| FCF Per Share | $0.28 |
Margins
Gross margin is 58.86%, with operating and profit margins of 1.69% and -3.04%.
| Gross Margin | 58.86% |
| Operating Margin | 1.69% |
| Pretax Margin | -2.28% |
| Profit Margin | -3.04% |
| EBITDA Margin | 7.16% |
| EBIT Margin | 0.92% |
| FCF Margin | 10.44% |
Dividends & Yields
HBIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.43% |
| Shareholder Yield | -2.43% |
| Earnings Yield | -1.98% |
| FCF Yield | 6.80% |
Analyst Forecast
The average price target for HBIO is $7.00, which is 76.32% higher than the current price. The consensus rating is "Buy".
| Price Target | $7.00 |
| Price Target Difference | 76.32% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on November 4, 2013. It was a forward split with a ratio of 1319:1000.
| Last Split Date | Nov 4, 2013 |
| Split Type | Forward |
| Split Ratio | 1319:1000 |
Scores
HBIO has an Altman Z-Score of 1.16 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.16 |
| Piotroski F-Score | 5 |